Pharmaceutical Executive covered a real-world study of adults over age 55 with obesity or overweight that found sustained Zepbound use was associated with lower monthly healthcare costs over time compared with untreated matched controls.
The article also connected the study to Susan Thomas’s perspective on GLP-1 coverage, noting that plan sponsors often focus on the immediate cost of therapy rather than the longer-term return. For LucyRx, the coverage reinforces the need for GLP-1 strategies that connect clinical evidence, benefit design, population needs and total cost over time.
Share